AcelRx Pharmaceuticals, Inc.
ACRX
Price:
$0.86
Market Cap:
$14.58M
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2011-02-11
Stock Exchange
NASDAQ
Ticker
ACRX
The ROE as of September 2024 (TTM) for AcelRx Pharmaceuticals, Inc. (ACRX) is -48.62%
According to AcelRx Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -48.62%. This represents a change of 321.00% compared to the average of -11.55% of the last 4 quarters.
AcelRx Pharmaceuticals, Inc. (ACRX) Historical ROE (quarterly & annually)
How has ACRX ROE performed in the past?
The mean historical ROE of AcelRx Pharmaceuticals, Inc. over the last ten years is 14.07%. The current -48.62% ROE has changed -445.61% with respect to the historical average. Over the past ten years (40 quarters), ACRX's ROE was at its highest in in the June 2022 quarter at 213.21%. The ROE was at its lowest in in the September 2016 quarter at -348.47%.
Average
14.07%
Median
85.11%
Minimum
-1108.61%
Maximum
808.64%
AcelRx Pharmaceuticals, Inc. (ACRX) ROE by Quarter and Year
Discovering the peaks and valleys of AcelRx Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 123.87%
Maximum Annual ROE = 808.64%
Minimum Annual Increase = -1197.44%
Minimum Annual ROE = -1108.61%
| Year | ROE | Change |
|---|---|---|
| 2023 | -72.93% | -133.31% |
| 2022 | 218.92% | 123.87% |
| 2021 | 97.79% | 35.01% |
| 2020 | 72.43% | -43.65% |
| 2019 | 128.54% | -111.60% |
| 2018 | -1108.61% | -885.78% |
| 2017 | 141.08% | -82.55% |
| 2016 | 808.64% | -1197.44% |
| 2015 | -73.68% | 3.07% |
| 2014 | -71.49% | 123.25% |
AcelRx Pharmaceuticals, Inc. (ACRX) Average ROE
How has ACRX ROE performed in the past?
The current ROE of AcelRx Pharmaceuticals, Inc. (ACRX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
81.26%
5-year avg
88.95%
10-year avg
14.07%
AcelRx Pharmaceuticals, Inc. (ACRX) ROE vs. Peers
How is ACRX’s ROE compared to its peers?
AcelRx Pharmaceuticals, Inc.’s ROE is greater than Mallinckrodt plc (-117.04%), less than Lifecore Biomedical, Inc. (26.37%), greater than Lucy Scientific Discovery Inc. (-377.80%), greater than Alimera Sciences, Inc. (-33.70%), less than Adamis Pharmaceuticals Corporation (0.93%), greater than Shuttle Pharmaceuticals Holdings, Inc. (-217.58%), greater than Catalent, Inc. (-26.99%), greater than Tilray Brands, Inc. (-6.77%), less than Aquestive Therapeutics, Inc. (36.59%), greater than Evoke Pharma, Inc. (-964.02%), greater than Guardion Health Sciences, Inc. (-71.26%), greater than Organogenesis Holdings Inc. (-2.77%), less than Agile Therapeutics, Inc. (104.04%), greater than Assertio Holdings, Inc. (-231.03%), greater than Amneal Pharmaceuticals, Inc. (-1322.15%),
| Company | ROE | Market cap |
|---|---|---|
| -117.04% | $4.52M | |
| 26.37% | $157.89M | |
| -377.80% | $906.91K | |
| -33.70% | $301.29M | |
| 0.93% | $7.25M | |
| -217.58% | $3.76M | |
| -26.99% | $10.92B | |
| -6.77% | $1.52B | |
| 36.59% | $453.02M | |
| -964.02% | $3.47M | |
| -71.26% | $12.79M | |
| -2.77% | $377.18M | |
| 104.04% | $10.43M | |
| -231.03% | $115.83M | |
| -1322.15% | $2.72B |
Build a custom stock screener for AcelRx Pharmaceuticals, Inc. (ACRX) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like AcelRx Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
AcelRx Pharmaceuticals, Inc. (ACRX) and other stocks custom spreadsheet templates
The easiest way to analyze a company like AcelRx Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is AcelRx Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for AcelRx Pharmaceuticals, Inc. (ACRX)?
What is the highest ROE for AcelRx Pharmaceuticals, Inc. (ACRX)?
What is the 3-year average ROE for AcelRx Pharmaceuticals, Inc. (ACRX)?
What is the 5-year average ROE for AcelRx Pharmaceuticals, Inc. (ACRX)?
How does the current ROE for AcelRx Pharmaceuticals, Inc. (ACRX) compare to its historical average?